TL;DR: Mandelic acid has a molecular weight roughly twice that of glycolic, which sounds like a disadvantage and is actually the point. The slower, larger molecule penetrates more evenly, irritates less, and shows the best peel-data for Fitzpatrick IV through VI skin in the trials that actually included those patients. Here is what the literature shows, what the marketing skips, and how I use it.
A reader with melasma and Fitzpatrick V skin sent me a thread of failed peel attempts. Glycolic, two months, post-inflammatory hyperpigmentation worsened. Salicylic, six weeks, fine but no improvement. TCA at a med spa, one session, dark patches she is still treating fourteen months later. She wanted to know what was wrong with her skin. Nothing was wrong with her skin. The acids were chosen wrong, and the data that should have informed those choices is not the data most cosmetic clinics use.
This piece is about mandelic acid, which is the exfoliant I now reach for first when the patient is Fitzpatrick IV, V, or VI, when post-inflammatory hyperpigmentation is on the table, or when the goal is the slow improvement rather than the dramatic one. It is also about why the standard acid hierarchy, which puts glycolic at the top because it is the most studied, has been quietly miscalibrated for the entire range of skin tones outside the Northern European phenotype.
I am going to be careful with my claims here. Mandelic is not magic. It is not faster than glycolic. It is, on the available evidence, the safer first-choice acid for the population that has historically been excluded from the trials.
What the studies actually show
Garg, Sinha, and Sarkar’s 2009 comparative trial (PMID: 19018817) is the paper I keep open when I am thinking about this. They compared thirty-five percent glycolic acid peels to a salicylic-mandelic acid combination peel in patients with active acne, post-acne scarring, and post-inflammatory hyperpigmentation. The cohort was Indian, which is to say Fitzpatrick III through V. Both peels improved acne. Both improved scarring modestly. The salicylic-mandelic combination produced significantly less side-effect burden, particularly post-peel hyperpigmentation, and the pigment outcomes were better on the mandelic side at the twelve-week mark.
This is not a one-off finding. Sarkar, Ghunawat, and Garg’s 2019 three-arm comparison (PMID: 31619888) put glycolic, salicylic-mandelic, and a phytic-acid combination peel against each other in active acne and post-acne pigmentation. The salicylic-mandelic arm had the best pigment outcomes and the lowest side-effect rate. The phytic combination was competitive. The glycolic arm produced the most post-peel dyschromia. The authors are explicit in their discussion: in skin of color, the standard glycolic protocol carries an irritation cost that often nets out to worse pigmentation than what the patient came in with.
Davis and Callender’s 2010 review of post-inflammatory hyperpigmentation in skin of color (PMID: 20725554) is the larger context document. It is one of the few pieces of literature that takes the question seriously, which is itself worth flagging. Their summary, distilled: anything that produces a sustained inflammatory response in Fitzpatrick IV-VI skin risks triggering a melanocyte response that prolongs or worsens the original pigmentation problem. The choice of acid is therefore an inflammation question first, an exfoliation question second. The molecule that produces the least inflammation per unit of exfoliation wins.
This is where mandelic’s molecular weight matters. Mandelic acid weighs about 152 daltons. Glycolic weighs 76. The penetration rate of an alpha hydroxy acid is partly a function of molecular size, and the slower-penetrating molecule produces a more gradient exposure across the stratum corneum, which is to say less acute irritation at the surface and a longer dwell at depth. Sharad’s 2013 glycolic review (PMID: 24399880) is good on the comparative penetration pharmacology, and is honest about glycolic’s irritation profile being its main limitation in pigmented skin.
The Taylor and colleagues 2013 paper (PMID: 23377327) is smaller but worth reading. It documented sustained melasma and post-inflammatory hyperpigmentation improvement on a mandelic-malic acid topical regimen, in a cohort that included Fitzpatrick III through V patients. The results were modest. The side-effect profile was clean. This is the pattern across most of the mandelic literature. Modest, durable, side-effect-light.
The marketing problem
If mandelic is so good, you might ask, why is glycolic still the default in most clinic-grade products and most consumer brands. The honest answer is partly historical inertia, partly that glycolic has more total trial volume, and partly that the patients who do best on mandelic have been underrepresented in the trials that drove the original product formulations.
Most of the glycolic literature was developed in the 1990s and early 2000s in patient populations that skewed Fitzpatrick I through III. The efficacy data is real. The safety data, in the populations studied, is real. The problem is the extrapolation. When the product is then marketed and sold to a Fitzpatrick V patient, the safety profile shifts and the irritation cost is not the same. The papers that documented this shift are mostly from Indian, Brazilian, and East Asian dermatology journals, which historically had less reach in the cosmetic chemistry trade press.
Mandelic acid was characterized as a peeling agent later, mostly in the early 2000s, and the trials that drove its adoption happened to include more skin-of-color patients from the start, partly because the principal investigators were in those countries. The literature on mandelic is smaller in total volume than the glycolic literature, but it is more representative of the patient population for whom the acid is the better choice.
This is not a conspiracy. It is a publication-volume artifact, compounded by a marketing tradition that takes the largest trial as the best trial. In skin of color, the largest trial is often the wrong one to base your decision on.
How I actually use mandelic acid
The product category, for what it is worth, is in a strange place. The mandelic-acid serums on the market range from poorly formulated solutions that crash out at room temperature to well-buffered five and ten-percent products that are clinically reasonable. The Garden of Wisdom mandelic, the Naturium mandelic at twelve percent, the By Wishtrend at five percent, and a handful of formulary-grade options are the ones I have seen work consistently. I am not going to recommend a single product because formulations change quarterly. The variables to check are the percentage, the pH, and the inclusion of buffering acids or chelators that stabilize the formula.
A reasonable starting protocol for an adult patient with Fitzpatrick IV-VI skin and a mixed pigmentation and texture concern looks like this. Begin at five percent mandelic, three nights a week, alongside a basic moisturizing routine. Sunscreen non-negotiable. After three weeks at five percent, if tolerance is good, increase frequency to four or five nights. After eight weeks total, consider stepping to a ten or twelve percent product, still nightly or alternate-night. Do not stack with retinoids in the same evening. Do not introduce a second exfoliant in the same routine. Patience is the protocol.
For active acne with post-acne pigmentation, the salicylic-mandelic combination is what the trials actually support. A two-percent salicylic, ten-percent mandelic blend, used three nights a week, is the closest consumer-product approximation to what the Garg and Sarkar studies used. The pigment improvement is slower than glycolic in the published comparisons, but the side-effect-adjusted outcomes are better.
For melasma specifically, mandelic is one piece. Sun protection, including tinted mineral SPF with iron oxide, is the larger piece. Azelaic acid is another piece. Mandelic alone is not a sufficient melasma protocol. None of the published trials make that claim.
The honest uncertainty
I want to flag the limits of what we can say here. The mandelic literature is smaller than the glycolic literature. The longest comparative trials are sixteen weeks. There is no head-to-head mandelic versus glycolic study at concentrations consumers actually use in at-home products. The Taylor 2013 paper used a specific iontophoresis-plus-topical protocol that is not directly replicable at home.
What we do have is a consistent direction of effect. Across the available comparative peel literature in skin of color, mandelic produces better pigment outcomes and fewer adverse events than glycolic at clinically equivalent exfoliation. That is the claim I am willing to defend. The claim that mandelic is universally superior to glycolic is not supported by the data, and would not survive a head-to-head in Fitzpatrick I-II patients with no pigment risk.
The other honest piece. Some patients do better on glycolic. The molecule-by-skin-type matching is not absolute. I have seen Fitzpatrick V patients tolerate eight percent glycolic with excellent outcomes, and Fitzpatrick II patients react badly to mandelic. The population-level data points one way. The individual response is its own variable, and a four-week trial at conservative concentration is the only way to know.
What I would tell my past self
Stop assuming the most-studied acid is the best acid for the patient in front of you. The trials were not all designed to answer the question you are asking. Read the Garg and Sarkar papers before reaching for the glycolic. The molecular weight question is real, and it matters in a way that the cosmetic chemistry trade press has been slow to acknowledge.
For Fitzpatrick IV-VI skin with pigment concerns, mandelic is the starting acid. Glycolic is the escalation if mandelic underdelivers, not the default. This is the inversion of what most product hierarchies recommend, and it is the inversion the trial data supports.
Move slowly. Mandelic does not show dramatic week-two results the way a stronger glycolic peel does. The improvement is sixteen to twenty weeks of steady use, with sun protection as the load-bearing variable for the pigmentation half of the equation. If you are looking for a fast acid, mandelic will disappoint you. If you are looking for a durable result with low risk of post-inflammatory worsening, mandelic is what the evidence supports.
FAQ
Is mandelic acid safe for sensitive skin?
On the available evidence, yes, more so than glycolic at equivalent concentrations. The larger molecule and slower penetration produce less acute irritation. Sensitive skin in the rosacea or atopic dermatitis category should still patch test, and any acid is best held during an active barrier flare.
Can I use mandelic with niacinamide and retinol?
Mandelic with niacinamide, yes, in the same routine. Mandelic with a retinoid, alternate nights, not the same evening. The combined irritation, even with mandelic’s gentler profile, is more than most skin tolerates over time.
What percentage of mandelic should I start with?
Five percent for three to six weeks, then ten percent if tolerated. Twelve to fifteen percent products exist and are reasonable for experienced users, but the marginal benefit over ten percent is modest and the irritation curve steepens.
Is mandelic acid effective for melasma?
Modestly, as one piece of a multi-step protocol. Sun protection is the largest variable for melasma. Mandelic, azelaic acid, and tranexamic acid topicals are the supporting cast. No single topical fixes melasma in isolation.
How long until I see results on post-inflammatory hyperpigmentation?
The comparative trials run twelve to sixteen weeks. Meaningful pigment improvement typically shows at eight to twelve weeks of consistent use. If nothing has changed at sixteen weeks, the acid is probably not the right tool and a pigment-specific protocol is the next step.
Related Elelaf tools
Sources
- Taylor MB, Yanaki JS, Draper DO, Shurtz JC. ‘Successful short-term and long-term treatment of melasma and postinflammatory hyperpigmentation using vitamin C with a full-face iontophoresis mask and a mandelic/malic acid skin care regimen.’ Journal of Drugs in Dermatology, 2013;12(1):45-50. PMID: 23377327.
- Garg VK, Sinha S, Sarkar R. ‘Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study.’ Dermatologic Surgery, 2009;35(1):59-65. PMID: 19018817.
- Sarkar R, Ghunawat S, Garg VK. ‘Comparative study of 35% glycolic acid, 20% salicylic-10% mandelic acid, and phytic acid combination peels in the treatment of active acne and postacne pigmentation.’ Journal of Cutaneous and Aesthetic Surgery, 2019;12(3):158-163. PMID: 31619888.
- Davis EC, Callender VD. ‘Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color.’ Journal of Clinical and Aesthetic Dermatology, 2010;3(7):20-31. PMID: 20725554.
- Sharad J. ‘Glycolic acid peel therapy – a current review.’ Clinical, Cosmetic and Investigational Dermatology, 2013;6:281-288. PMID: 24399880.